Tag: antares pharma
March 3, 2020
Antares Pharma Reports Q4 and Full Year 2019 Financial Results
Antares Pharma reported operating and financial results for the fourth quarter and full year ended December 31, 2019. January 27, 2020
Antares Announces 2020 Revenue Guidance Range of up to US$155 Million
Antares announced its 2020 net revenue guidance of US$135 to US$155 million, which includes potential revenue scenarios for AMAG’s Makena.
November 28, 2018
Antares’ Device Aids Teva’s Generic EpiPen Launch
The EpiPen and this generic equivalent are indicated for the emergency treatment of severe allergic reactions. November 27, 2018
Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen
Antares Pharma (NASDAQ:ATRS) announced that Teva Pharmaceutical Industries generic EpiPen is now commercially available in limited quantities. As quoted in the... October 1, 2018
Antares Receives FDA Approval of Xyosted (Testosterone Enanthate) Injection for Testosterone Replacement Therapy
Antares Pharma (NASDAQ:ATRS) today announced the approval of XYOSTED (testosterone enanthate) injection by the U.S. Food and Drug Administration (FDA).... August 17, 2018
